PharmaxTM topical creams use exclusive patented trans-dermal DelivraTM technology

PharmaxTM, a leading-edge, comprehensive line of professional grade nutraceutical products announced its Topical PROTM series of creams use the innovative clinically studied DelivraTM trans-dermal technology from Delivra Inc. Following a recent multi-million dollar investment, this unique technology and specific PharmaxTM products will be the subject of a large scale research project spearheaded by Dr. Joseph Gabriele, the developer of the DelivraTM technology and a close and long-time collaborator of PharmaxTM. The DelivraTM trans-dermal technology takes advantage of established interactions between natural substances and human cellular and nerve tissues to address pain management without the side effects associated with typical interventions. “In 2011, we were first-to-market exclusively for the healthcare practitioner segment with novel natural topical creams using the Delivra delivery system,” said Yves Yau, Head of the PharmaxTM brand. “We are proud of this latest advancement that emphasizes our ongoing commitment to provide only the highest quality, research-driven products offering cutting-edge ingredients. The new research project and our close collaboration with Dr. Joseph Gabriele will continue to place PharmaxTM at the forefront of trans-dermal technology.”